Primary Outcome
Figure 2 · Panel Primary_Outcomes
Panel Primary_Outcomes 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Yangyang Tang, Wenjie Li, Zhiyan Wang, Shuk Han Chu, Yanfang Wu, Zhaoxu Jia, Chang Hua, Hao Zhang, Xinru Liu, Qiang Lv, Chao Jiang, Jian-Zeng Dong, Chang-Sheng Ma, Xin Du
Open Heart 12(2) e003487
BACKGROUND: The minimally important difference (MID) for frailty variation associated with adverse outcomes remains unknown in patients with heart failure and preserved ejection fraction (HFpEF), and whether spironolactone can ameliorate frailty progression in this population remains unclear. METHODS: We analysed data from 1767 participants in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. The MID for frailty was calculated using an anchor-based approach, with the EuroQol-Visual Analogue Scale (EQ-VAS) as the anchor. Frailty index (FI), defined as a 35-item cumulative deficit score, and EQ-VAS were assessed at baseline and 1-year follow-up. The primary composite outcome (cardiovascular death, aborted cardiac arrest or heart failure hospitalisation) was assessed from the 1-year follow-up visit. Adjusted Cox proportional hazards models evaluated the link between FI changes (ΔFI≥MID) and the primary outcome. Longitudinal FI changes were analysed using linear mixed-effects models to evaluate spironolactone's effect. RESULTS: The MID for the FI was 0.03 points. An FI reduction ≥MID was associated with a lower risk of the primary composite outcome (aHR, 0.63; 95% CI 0.48 to 0.82), all-cause mortality (aHR, 0.57; 95% CI 0.42 to 0.76) and heart failure hospitalisation (aHR, 0.55; 95% CI 0.40 to 0.75) after adjusting for baseline FI, age, sex, New York Heart Association class, smoking status and treatment assignment. No between-group difference in FI change was observed with spironolactone versus placebo (aOR, 0.85; 95% CI 0.67 to 1.09). CONCLUSIONS: Frailty improvement exceeding the 0.03 FI threshold predicts better prognosis in HFpEF, underscoring the value of routine assessment. Spironolactone use was associated with neutral effects on frailty progression in our analysis, suggesting potential safety in this vulnerable population. TRIAL REGISTRATION NUMBER: NCT00094302.
1 个 Figure · 3 个 KM 面板
Figure 2. Kaplan-Meier estimation of adverse outcomes by FI change groups. The primary outcome was a composite of cardiovascular mortality, aborted cardiac arrest and heart failure hospitalisation. Models adjusted for baseline FI, age, sex, New York Heart Association and smoking. FI, frailty index; HF, heart failure.
Figure 2 · Panel Primary_Outcomes
Panel Primary_Outcomes 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel All-Cause_Mortality
Panel All-Cause_Mortality 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel HF_hospitalization
Panel HF_hospitalization 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。